{
    "Trade/Device Name(s)": [
        "HYDRASHIFT 2/4 daratumumab",
        "Daratumumab Control"
    ],
    "Submitter Information": "Sebia, Inc.",
    "510(k) Number": "K172195",
    "Predicate Device Reference 510(k) Number(s)": [
        "K960669"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFF",
        "JJY"
    ],
    "Summary Letter Date": "December 07, 2017",
    "Summary Letter Received Date": "December 12, 2017",
    "Submission Date": "January 4, 2018",
    "Regulation Number(s)": [
        "21CFR866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, and E immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Monoclonal proteins",
        "IgG",
        "IgA",
        "IgM",
        "Kappa light chain",
        "Lambda light chain",
        "Daratumumab"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "HYDRASYS 2 electrophoresis apparatus"
    ],
    "Method(s)/Technology(ies)": [
        "Immunofixation electrophoresis",
        "Agarose gel electrophoresis"
    ],
    "Methodologies": [
        "Immunofixation"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Sebia HYDRASHIFT 2/4 daratumumab assay and control for qualitative detection of monoclonal proteins in human serum using immunofixation electrophoresis.",
    "Indications for Use Summary": "For qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis, enabling assessment in patients who have received daratumumab therapy; control is for quality control of this procedure using HYDRASYS 2.",
    "fda_folder": "Immunology"
}